Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial
Saundra S. Buys(University of Utah), John K. Gohagan(National Institutes of Health), David Chia(University of California, Los Angeles), Christine Cole Johnson(Henry Ford Health System), Mona N. Fouad(University of North Texas), Lawrence R. Ragard(Westat (United States)), Mark H. Greene(Cancer Institute (WIA)), Edward E. Partridge(University of Alabama at Birmingham), Richard M. Fagerstrom(United States Department of Health and Human Services), Douglas J. Reding(Ascension), Thomas L. Riley(Automation, Information, and Management Systems (United States)), Grant Izmirlian(National Institutes of Health), Patricia Hartge(National Institutes of Health), Philip C. Prorok(National Cancer Institute)
Cited by 345
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Body-Mass Index and Mortality among 1.46 Million White Adults
|New England Journal of Medicine|2010|2.3k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k